Why the study?
Does higher medication adherence to RAAS inhibitors and statins lower Medicare spending among beneficiaries with diabetes?
Population
Medicare beneficiaries with diabetes
Comparison
Higher adherence to renin-angiotensin-aldosterone… vs Lower adherence to RAAS inhibitors and statins
Design
Cohort
Follow-up
3 years
Authors
Loading...
Supports adherence programs in diabetic Medicare beneficiaries; extends observational links but leaves causal spending effects open.
Does higher medication adherence to RAAS inhibitors and statins lower Medicare spending among beneficiaries with diabetes?
Higher adherence to RAAS inhibitors and statins in Medicare beneficiaries with diabetes is associated with significant reductions in cumulative Medicare spending over 3 years.
Stuart et al. (2011) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: